新的帕克洛维德数据报告。
New Data on Paxlovid Reported.
出版信息
Am J Nurs. 2022 Oct 1;122(10):59. doi: 10.1097/01.NAJ.0000890244.62778.a4.
Abstract
According to this study: In a phase 2/phase 3 study of Paxlovid use in patients at standard risk for developing severe COVID-19, the primary end point of self-reported sustained alleviation of all symptoms for four consecutive days wasn't met.A nonsignificant risk reduction in hospitalizations and death was seen in a subgroup of patients who had at least one risk factor for severe COVID-19.
摘要
根据这项研究
在一项针对有发展为重症 COVID-19 标准风险的患者使用 Paxlovid 的 2/3 期研究中，主要终点为自我报告的所有症状连续四天持续缓解并未达到。在至少有一个重症 COVID-19 风险因素的患者亚组中，住院和死亡的风险降低没有统计学意义。
相似文献
1
New Data on Paxlovid Reported.
Am J Nurs. 2022 Oct 1;122(10):59. doi: 10.1097/01.NAJ.0000890244.62778.a4.
2
Hospitalization and Emergency Department Encounters for COVID-19 After Paxlovid Treatment - California, December 2021-May 2022.
MMWR Morb Mortal Wkly Rep. 2022 Jun 24;71(25):830-833. doi: 10.15585/mmwr.mm7125e2.
3
Public Health Impact of Paxlovid as Treatment for COVID-19, United States.
Emerg Infect Dis. 2024 Feb;30(2):262-269. doi: 10.3201/eid3002.230835. Epub 2024 Jan 5.
4
Paxlovid in patients who are immunocompromised and hospitalised with SARS-CoV-2 infection.
Lancet Infect Dis. 2022 Sep;22(9):1279. doi: 10.1016/S1473-3099(22)00430-3. Epub 2022 Jul 14.
5
Three more points about Paxlovid for covid-19.
BMJ. 2022 Jun 7;377:o1397. doi: 10.1136/bmj.o1397.
6
Special Considerations for Paxlovid Treatment Among Transplant Recipients With SARS-CoV-2 Infection.
Am J Kidney Dis. 2022 Apr;79(4):480-482. doi: 10.1053/j.ajkd.2022.01.001. Epub 2022 Jan 12.
7
A pilot study on Paxlovid therapy for hemodialysis patients with severe acute respiratory syndrome coronavirus 2 infections.
Front Med. 2024 Feb;18(1):169-179. doi: 10.1007/s11684-023-1011-0. Epub 2023 Nov 18.
8
Interactions listed in the Paxlovid fact sheet, classified according to risks, pharmacological groups, and consequences.
Rev Esp Quimioter. 2022 Aug;35(4):357-361. doi: 10.37201/req/054.2022. Epub 2022 Jul 13.
9
Exploring Paxlovid Efficacy in COVID-19 Patients with MAFLD: Insights from a Single-Center Prospective Cohort Study.
Viruses. 2024 Jan 12;16(1):112. doi: 10.3390/v16010112.
10
African clinical trial denied access to key COVID drug Paxlovid.
Nature. 2022 Apr;604(7906):412-413. doi: 10.1038/d41586-022-00919-5.
引用本文的文献
1
Nirmatrelvir combined with ritonavir for preventing and treating COVID-19.
Cochrane Database Syst Rev. 2023 Nov 30;11(11):CD015395. doi: 10.1002/14651858.CD015395.pub3.
2
Aprotinin-Drug against Respiratory Diseases.
Int J Mol Sci. 2023 Jul 6;24(13):11173. doi: 10.3390/ijms241311173.
Zotero 插件